PriceTargets.com logo

NASDAQ:NPCE - NeuroPace Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $13.10
  • Forecasted Upside: 139.05 %
  • Number of Analysts: 5
  • Breakdown:
  • 1 Sell Ratings
  • 1 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$5.48 As of 08/12/2022 06:17 PM ET
▼ -0.41 (-6.96%)

This chart shows the closing price for NPCE by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New NeuroPace Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for NPCE and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for NPCE

Analyst Price Target is $13.10
▲ +139.05% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for NeuroPace in the last 3 months. The average price target is $13.10, with a high forecast of $26.00 and a low forecast of $5.50. The average price target represents a 139.05% upside from the last price of $5.48.

This chart shows the closing price for NPCE for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Hold

The current consensus among 5 contributing investment analysts is to hold stock in NeuroPace. This rating has held steady since May 2022, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/18/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
5/19/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
8/17/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
11/15/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
2/13/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
5/14/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
7/13/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
8/12/2022

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
7/15/2022Morgan StanleyLower Price TargetUnderweight$6.00 ➝ $5.50Low
4/5/2022Wolfe ResearchInitiated CoverageOutperform$13.00Low
3/11/2022Wells Fargo & CompanyLower Price TargetEqual Weight$11.00 ➝ $9.00High
3/11/2022SVB LeerinkLower Price TargetOutperform$15.00 ➝ $12.00High
1/19/2022Wells Fargo & CompanyDowngradeOverweight ➝ Equal Weight$11.00High
1/7/2022Morgan StanleyDowngradeEqual Weight ➝ Underweight$17.00 ➝ $12.00High
11/14/2021SVB LeerinkReiterated RatingBuy$30.00Low
11/11/2021Morgan StanleyDowngradeOverweight ➝ Equal Weight$24.00 ➝ $17.00High
11/11/2021Wells Fargo & CompanyLower Price TargetOverweight$28.00 ➝ $20.00High
8/17/2021Robert W. BairdInitiated CoverageOutperform$26.00Medium
8/15/2021SVB LeerinkReiterated RatingBuy$30.00Medium
6/3/2021SVB LeerinkBoost Price TargetOutperform$25.00 ➝ $30.00Low
5/17/2021SVB LeerinkInitiated CoverageOutperform$25.00Medium
5/17/2021Wells Fargo & CompanyInitiated CoverageOverweight$25.00Medium
5/17/2021JPMorgan Chase & Co.Initiated CoverageOverweight$27.00Medium
5/17/2021Morgan StanleyInitiated CoverageOverweight$26.00Medium
(Data available from 8/12/2017 forward)

News Sentiment Rating

0.60 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 1 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
1/14/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/13/2022
  • 2 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/15/2022
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/14/2022
  • 0 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
5/14/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/13/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/13/2022
  • 3 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/12/2022

Current Sentiment

  • 3 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

NeuroPace logo
NeuroPace, Inc. operates as a medical device company in the United States. It develops and sells RNS system, a brain-responsive neuromodulation system for treating medically refractory focal epilepsy by delivering personalized real-time treatment at the seizure source. The company's RNS system also records continuous brain activity data; and enables clinicians to monitor patients in person and remotely. It sells its products to hospital facilities for initial RNS system implant procedures and for replacement procedures. The company was incorporated in 1997 and is headquartered in Mountain View, California.
Read More

Today's Range

Now: $5.48
Low: $5.37
High: $5.80

50 Day Range

MA: $5.60
Low: $4.95
High: $6.30

52 Week Range

Now: $5.48
Low: $4.61
High: $24.65

Volume

31,960 shs

Average Volume

61,037 shs

Market Capitalization

$134.84 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.54

Frequently Asked Questions

What sell-side analysts currently cover shares of NeuroPace?

The following Wall Street analysts have issued stock ratings on NeuroPace in the last year: Morgan Stanley, Robert W. Baird, SVB Leerink LLC, Wells Fargo & Company, and Wolfe Research.
View the latest analyst ratings for NPCE.

What is the current price target for NeuroPace?

5 Wall Street analysts have set twelve-month price targets for NeuroPace in the last year. Their average twelve-month price target is $13.10, suggesting a possible upside of 139.1%. Robert W. Baird has the highest price target set, predicting NPCE will reach $26.00 in the next twelve months. Morgan Stanley has the lowest price target set, forecasting a price of $5.50 for NeuroPace in the next year.
View the latest price targets for NPCE.

What is the current consensus analyst rating for NeuroPace?

NeuroPace currently has 1 sell rating, 1 hold rating and 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in NPCE, but not buy more shares or sell existing shares.
View the latest ratings for NPCE.

What other companies compete with NeuroPace?

Other companies that are similar to NeuroPace include DarioHealth, Profound Medical, Lucid Diagnostics, TELA Bio and Asensus Surgical. Learn More about companies similar to NeuroPace.

How do I contact NeuroPace's investor relations team?

The company's listed phone number is 650-237-2700 and its investor relations email address is [email protected] The official website for NeuroPace is www.neuropace.com. Learn More about contacing NeuroPace investor relations.